Seattle-based Presage Biosciences has been funded with $13 million in fresh funds from Celgene, a New Jersey-based biopharmaceutical company. Presage is the developer of a patented drug array platform that analyzes cancer drug combinations. The strategic investment will allow Celgene to take advantage of the Presage platform to identify novel drug combinations for solid tumor indications.
